American Medical Care Continues to Lag: AcrySof® IQ ReSTOR® Multifocal Toric IOL Released Outside the USA

Alcon labs announced this week the release of the AcrySof^® IQ ReSTOR^® Multifocal Toric intraocular lens (IOL) outside the United State.  The AcrySof® IQ ReSTOR® Multifocal Toric IOL combines the technologies of the ReSTOR® +3 add multifocal IOL and the Toric IOL.  Data demonstrated that the AcrySof^® IQ ReSTOR^® Multifocal Toric IOL delivers similar quality of vision when compared to the AcrySof^® IQ ReSTOR^® +3.0 D IOL.

This lens will allow surgeons to offer their patients who have pre-existing astigmatism a lens that provides quality vision at all distances after cataract surgery or clear lens exchange. Up until now, I have treated these patients with the ReSTOR^® Multifocal implanted at the time of cataract surgery.  Residual astigmatism is then treated about 1 month later with LASIK.  This new lens will allow me to treat both conditions at the same time, and use less surgery. 

There is only 1 problem:  this new lens is NOT AVAILABLE IN THE UNITED STATES!  Alcon plans to file a Pre-Market Application (PMA) for the lens with the U.S. Food and Drug Administration (FDA) in early 2012.  Once again, the draconian ways of our FDA have allowed medical care outside the US to out pace our own, we continue to provide third world medical technology to our patients...  Another part of our broken health care system in need of repair.